Alkermes (ALKS) Projected to Post Earnings on Wednesday

Alkermes (NASDAQ:ALKS) is expected to announce its Q4 2025 results before the market opens on Wednesday, February 11th. Analysts expect Alkermes to post earnings of $0.43 per share and revenue of $380.4410 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Friday, February 13, 2026 at 12:30 PM ET.

Alkermes Trading Down 1.4%

NASDAQ:ALKS opened at $34.47 on Wednesday. The stock has a market capitalization of $5.69 billion, a P/E ratio of 17.06 and a beta of 0.49. Alkermes has a 1 year low of $25.17 and a 1 year high of $36.45. The firm has a 50 day moving average of $30.06 and a 200-day moving average of $29.46.

Insider Buying and Selling

In other Alkermes news, EVP Craig C. Hopkinson sold 9,000 shares of the firm’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $33.93, for a total value of $305,370.00. Following the completion of the transaction, the executive vice president directly owned 57,740 shares in the company, valued at $1,959,118.20. This trade represents a 13.49% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Shane Cooke sold 61,200 shares of the company’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $34.57, for a total value of $2,115,684.00. Following the sale, the director owned 103,744 shares in the company, valued at approximately $3,586,430.08. This represents a 37.10% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 148,148 shares of company stock valued at $5,028,378. Insiders own 4.40% of the company’s stock.

Institutional Investors Weigh In On Alkermes

A number of institutional investors and hedge funds have recently modified their holdings of the company. Credit Agricole S A acquired a new stake in Alkermes in the third quarter valued at about $280,000. Vise Technologies Inc. boosted its stake in shares of Alkermes by 26.8% in the 3rd quarter. Vise Technologies Inc. now owns 10,809 shares of the company’s stock valued at $324,000 after purchasing an additional 2,286 shares in the last quarter. Orion Porfolio Solutions LLC grew its holdings in shares of Alkermes by 4.5% during the 3rd quarter. Orion Porfolio Solutions LLC now owns 8,762 shares of the company’s stock valued at $263,000 after purchasing an additional 376 shares during the last quarter. Tower Research Capital LLC TRC increased its position in Alkermes by 88.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 13,710 shares of the company’s stock worth $392,000 after purchasing an additional 6,437 shares in the last quarter. Finally, Boothbay Fund Management LLC bought a new position in Alkermes in the 2nd quarter valued at approximately $286,000. 95.21% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research firms have recently commented on ALKS. Piper Sandler reaffirmed an “overweight” rating and set a $45.00 price target (up previously from $38.00) on shares of Alkermes in a research note on Thursday, October 23rd. Deutsche Bank Aktiengesellschaft cut their target price on shares of Alkermes from $55.00 to $45.00 and set a “buy” rating on the stock in a research report on Thursday, November 13th. Royal Bank Of Canada lifted their price target on shares of Alkermes from $45.00 to $47.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 22nd. Zacks Research upgraded shares of Alkermes from a “hold” rating to a “strong-buy” rating in a report on Tuesday, January 13th. Finally, Truist Financial raised their price objective on shares of Alkermes from $50.00 to $55.00 and gave the company a “buy” rating in a research note on Monday, November 17th. Two research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Alkermes presently has an average rating of “Moderate Buy” and an average price target of $44.69.

About Alkermes

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes’ portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.

Alkermes’ commercial franchise features several approved products.